Acarbose Cardiovascular Evaluation Trial
A Long-term, Multicentre, Double-blind, Randomised Parallel-group Trial to Determine Whether Reducing Post-prandial Glycaemia Can Reduce Cardiovascular-related Morbidity and Mortality in Patients With Established Coronary Heart Disease or Acute Coronary Syndrome Who Have Impaired Glucose Tolerance
Sponsor: Bayer
A PHASE4 clinical study on Acute Coronary Syndrome and Coronary Heart Disease, this trial is completed. The trial is conducted by Bayer and has accumulated 8 data snapshots since 2009. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Change History
8 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE4
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jan 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Feb 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- University of Oxford
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anshan, China, Baotou, China, Beijing, China, Cangzhou, China, Changchun, China, Changsha, China, Chengdu, China, Chifeng, China, Chongqing, China, Dalian, China and 48 more location s